ReviewDiabetology & metabolic syndrome2025
Brazilian guidelines for the management of osteoporosis in diabetes mellitus.
Review in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundComplications of diabetes mellitus are classically divided into microangiopathic and macroangiopathic categories, encompassing disorders affecting the retina, kidneys, nerves, and cardiovascular system. However, the complications associated with diabetes are broader, causing impaired immunity and increased susceptibility to cancer. Recently, diabetes, irrespective of type, has been recognized as a risk factor for fractures, which can impair quality of life and reduce life expectancy. This paper presents the joint stance of the Brazilian Society of Endocrinology and Metabolism and the Brazilian Diabetes Society on the management of osteoporosis in diabetes.
methodsThe guidelines were developed based on selected topics to be addressed, including fracture risk in diabetes, the osteoporosis diagnosis in diabetes, adjustments to the Fracture Risk Assessment Tool, the impact of treatment on skeletal health, the impact of osteoporosis treatment on metabolic control, and the efficacy of therapeutic agents for osteoporosis in individuals with diabetes. Each section reflects the consensus of 11 experts from the two societies, derived from a review of the best available evidence, including randomized clinical trials, meta-analyses, and high-quality observational studies related to the association between diabetes and osteoporosis. RESULTS AND
conclusionsA total of twelve recommendations were established. The first recommendation acknowledges types 1 and 2 diabetes as risk factors for fractures. Osteoporosis screening should commence in men and women aged 50 and older, provided there is a specific risk factor, such as duration exceeding 10 years. The safety profile of antidiabetic drugs concerning bone health should be considered for individuals at high fracture risk. Fall prevention is essential for fracture prevention. Antiresorptive drugs do not interfere with the metabolic control of diabetes, and bisphosphonates are deemed the most appropriate agents for primary fracture prevention in diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.